PanTher Featured on STAT Startup Spotlight
December 14, 2018
PanTher was featured on the STAT Startup Spotlight in December. Kate Sheridan provided an overview of the company technology and its status highlighting the interest of large pharma companies into the disruptive technology of our early-stage start-up. "Wherever there has been a stage for biotech entrepreneurs this fall, Laura Indolfi has appeared. And wherever she is, major pharmaceutical companies have been, too. Indolfi’s company, Cambridge, Mass.-based PanTher Therapeutics, has already received awards linked to Bristol-Myers Squibb and Johnson & Johnson. And on Tuesday, she competed for — and won — one of Amgen’s Golden Tickets — a one-year pass into LabCentral, the noted Cambridge lab-sharing space where PanTher is already headquartered."
Amgen awards PanTher a Golden Ticket to LabCentral
December 12, 2018
Amgen and LabCentral today announced that PanTher Therapeutics has won the Amgen Golden Ticket at LabCentral. The Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge, Mass. facility on Dec. 11, 2018. Six finalists pitched their business plans to attendees where the audience members' votes served as input for the Amgen internal committee's decision. The Golden Ticket represents one year of free bench space for one scientist, including benefit of LabCentral's shared infrastructure and services (such as conference rooms, permits, shared equipment and facilities, participation in LabCentral training modules and seminars). Amgen scientists also provide on-going mentoring throughout the year.
PanTher announces agreement with MD Anderson Cancer Center and appointment of senior clinical advisor
October 16, 2018
PanTher Therapeutics, the biotech company developing drug-delivery platforms for unresectable, locally advanced solid tumors, today announced an agreement with The University of Texas MD Anderson Cancer Center and the appointment of a new senior clinical advisor. The collaboration will support preclinical testing of PanTher’s lead product for pancreatic cancer, PTM-101, and is intended to demonstrate readiness for future human clinical trials.
PanTher to present at Bio Investor Forum
October 10, 2018
The company announced its scheduled presentation at the 2018 BIO Investor Forum being held in San Francisco, CA on October 17-18. Laura Indolfi, Founder and Chief Executive Officer (CEO), will present a company overview and will discuss PanTher platform and its application in solid tumor to provide localized and sustained delivery of therapy directly at the tumor side. The presentation is scheduled for Wednesday 17th at 10am PT.
MLSC & Takeda select PanTher's CEO for MassNextGen
June 20, 2018
Laura Indolfi was named one of the five winners of the Massachusetts Life Sciences Center (MLSC) Initiative for Women Entrepreneurs inaugural awards to support women in early-stage life sciences companies. Lt. Governor Karyn Polito announced the 2018 winners for the MLSC Massachusetts Next Generation Initiative (MassNextGen), a competitive program to support women entrepreneurs in early-stage life sciences companies. The public-private partnership, a five-year, $1.1 million commitment, focuses on empowering women and diversity in the next generation of life sciences entrepreneurs. Five women-led companies were selected as awardees through the MassNextGen program. Awardees represent a wide range of applications to improve human health. All five companies will receive access to a network of executive coaches for a year.
PanTher signs exclusive patent license agreement with MIT
March 25, 2018
PanTher has entered into an exclusive patent license agreement with the Massachusetts Institute of Technology (MIT) for exclusive rights to the technology developed in the laboratories of Dr. Elazer Edelman and Dr. Robert Langer at MIT as well as Dr. David Ting at MGH to provide localized and sustained delivery of chemotherapy directly at the tumor site. The licensed patents form the foundational intellectual property for PanTher's technology platform. "We are excited to be moving forward with development of PanTher's technology platform for localized drug delivery, which will ultimately give patients a much-needed additional option beyond systemic chemotherapy," said Dr. Laura Indolfi, CEO of PanTher Therapeutics, "this agreement with the Massachusetts Institute of Technology is an important step forward in getting this technology to the patients that need it." Under the terms of the agreement, PanTher will continue to maintain the patents in the agreement, as well as file new intellectual property based on any inventions in the course of product development.
PanTher's CEO to speak at "How to advance in Biotech"
June 15, 2017
Drug development relies on years of experience across the industry and exposure to multiple upstream and downstream elements in order to be prepared for the challenges in our unique field. If you're a young person working in drug or device development, what are the roles that will give you a broad set of experiences to prepare you for an eventual CEO role? Join us as we will discuss what needs to be done, and where you should put your energy today to be a leader in the field tomorrow. Hear from experts across the industry, from the investors who know what they're looking for when it comes to biotech leadership, the experienced CEO's who know what it takes, and some of the young people on the front lines of successful biotech startups.
Join us at the Convergence of Medical Devices & Drugs
May 12, 2017
Combination products are essential tools for patient care and continue to be an area of active and exciting development. From diffusion based polymer systems to complex delivery devices utilizing diagnostic sensors, a diverse set of scientific and engineering disciplines are being brought to bear within this space. However, combination products involve components normally developed under different types of regulations, design criteria and controls. This symposium will explore many of the diverse aspects impacting combination products. PanTher will be featured in the " Innovation and Development " Panel.
TEDMED Blog: The Hopeful Future of Precision Medicine
October 21, 2016
In 2015, President Obama funded the Precision Medicine Initiative to ensure that researchers could focus on creating efficient and effective ways to integrate more personalized treatment plans into the current healthcare and medical system. This year, we’re excited to be among some of the front-runners in the precision medicine movement on the TEDMED stage! Read about our vision of Precision Medicine to catalyze cancer research on the TEDMED Blog.
Bristol-Myers Squibb awards PanTher with 'Golden Ticket'
September 20, 2016
Bristol-Myers Squibb Company and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced that PanTher is one of the winners of Bristol-Myers Squibb’s Golden Tickets for LabCentral. As a platinum sponsor of LabCentral, Bristol-Myers Squibb can select up to two innovative life-sciences and biotech startup companies per year of active sponsorship for “Golden Tickets,” which underwrite the cost of one lab bench for one year in LabCentral’s Kendall Square facility.
PanTher will be at TEDMED in The Hive Program
July 14, 2016
PanTher is delighted to announce that we are among the 25 entrepreneurs and their organizations that have been selected for The TEDMED 2016 Hive Program. The Hive entrepreneurs will join the TEDMED stage program in a special session titled Audacious. TEDMED curates extraordinary people and ideas from all disciplines in pursuit of unexpected connections – to accelerate innovation in health and medicine.
PanTher's CEO presenting at WIRED Health-Startup Stage
April 29, 2016
WIRED Health is an annual exploration of the ever-changing world of healthcare, featuring leading technologists, entrepreneurs and innovators in sectors from robotics to virtual reality. On April 29, 2016, WIRED Health gathered 18 growth-stage companies to present their ideas, technologies and platforms on the Bupa Startup Stage. PanTher was one of them!
Springboard accepts PanTher in the Health Innovation Hub
March 4, 2016
Springboard is a highly-vetted expert network of innovators, investors and influencers who are dedicated to building high-growth technology-oriented companies led by women. PaTher has been accepted in the 2016 Health Innovation Hub, a year-long program for healthcare and life science companies,, to participate in several in-person and virtual workshops throughout the year that provide exposure to influencers, active investors, and potential strategic partners.
PanTher's CEO, Laura Indolfi, named a TED Fellow
December 8, 2015
Laura Indolfi, co-founder & CEO of PanTher Therapeutics has been selected as a TED Fellow, joining a class of 21 change-makers from around the world who will share their ideas worth spreading from the TED stage this February in Vancouver. The TED Fellows program brings together young innovators from around the world and across disciplines, who display both outstanding achievement and exemplary character, to ignite their careers.
PanTher selected to participate in MassCONNECT
October 27, 2015
MassCONNECT, the only entrepreneur mentorship program in Massachusetts that dives deep into the life sciences industry, has picked PanTher to participate in the 4th cycle of his program. Sponsored by Boehringer Ingelheim and Nixon Peabody LLP, the mentoring will take place in the offices of MassBio.
PanTher to present at the DOD SBIR Summit in December
September 18, 2015
PanTher will participate as one of the top 10% application in the Department of Defense SBIR Summit in Austin, Texas, December 1-3, 2015. This gives PanTher the possibility to deliver a presentation in the category "Defense Medical Technology Challenge" and to showcase our innovation at the reception.
May 13, 2015
PanTher is Finalist in the MIT 100K competition
MIT 100K, one of the largest and most famous business plan competitions in the world, has selected PanTher among the 8 finalists out of over 200 entries. Finalists in the Launch present onstage to a 1,200+ live audience from Cambridge, Boston, and beyond.